XIAP and inflammatory breast carcinoma: Van Berckelaer et al. (2024[62]) found that XIAP overexpression was observed in 76 % of inflammatory breast cancers versus 42 % of non-inflammatory cases, with reduced survival and increased NF-κB activity (Cai et al., 2017[6]).